Novo Nordisk's head of commercial strategy and corporate affairs, Camilla Sylvest, has decided to leave the company, the ...
Novo Nordisk has updated its Wegovy savings program, allowing eligible cash-paying patients to access the drug at retail ...
As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback